mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma
- PMID: 21240463
- DOI: 10.3892/or.2011.1146
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma
Abstract
Bladder cancer and head and neck squamous cell carcinoma (HNSCC) are frequent but lack efficient therapies especially in advanced disease. Almost no studies on mTOR function and inhibition in these tumor entities have been reported. We examined the gene and protein expression levels of mTOR and its activated form (pmTOR) in three human bladder carcinoma cell lines (RT-4, T24, EJ28) and three HNSCC cell lines (PCI-1, PCI-13, BHY). Furthermore, the consequences of mTOR inhibition by mTOR-specific siRNAs and the mTOR inhibitor temsirolimus were analysed in vitro using immunohistochemical Ki-67 staining, mTOR and pmTOR western blot analysis, MTT assay, as well as cell cycle analysis with flow cytometry. Especially pmTOR protein expression levels showed marked differences between cell lines. siRNA transfection was associated with dose-dependent target protein reduction but not proliferation inhibition or apoptosis. On the contrary, temsirolimus significantly reduced cell viability and induced apoptosis and cell cycle arrest. According to these data, bladder cancer and HNSCC are promising tumor entities for mTOR inhibition with temsirolimus.
Similar articles
-
Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.Head Neck. 2010 Dec;32(12):1619-28. doi: 10.1002/hed.21374. Head Neck. 2010. PMID: 20222045 Clinical Trial.
-
The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.Anticancer Res. 2011 Sep;31(9):2713-22. Anticancer Res. 2011. PMID: 21868512
-
Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.Cancer Prev Res (Phila). 2010 Dec;3(12):1586-95. doi: 10.1158/1940-6207.CAPR-09-0244. Epub 2010 Sep 17. Cancer Prev Res (Phila). 2010. PMID: 20851953
-
mTOR kinase inhibitors as a treatment strategy in hematological malignancies.Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Future Med Chem. 2012. PMID: 22416776 Review.
-
Current and future directions in mammalian target of rapamycin inhibitors development.Expert Opin Investig Drugs. 2011 Mar;20(3):381-94. doi: 10.1517/13543784.2011.541154. Epub 2011 Feb 8. Expert Opin Investig Drugs. 2011. PMID: 21299441 Review.
Cited by
-
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.J Transl Med. 2015 Apr 1;13:106. doi: 10.1186/s12967-015-0456-6. J Transl Med. 2015. PMID: 25890004 Free PMC article.
-
Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.BMC Urol. 2022 May 24;22(1):79. doi: 10.1186/s12894-022-01027-2. BMC Urol. 2022. PMID: 35610639 Free PMC article.
-
miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells.Onco Targets Ther. 2018 Jan 4;11:239-252. doi: 10.2147/OTT.S114276. eCollection 2018. Onco Targets Ther. 2018. PMID: 29379304 Free PMC article.
-
A phase II trial of temsirolimus in second-line metastatic urothelial cancer.Med Oncol. 2012 Dec;29(4):2870-6. doi: 10.1007/s12032-012-0216-x. Epub 2012 Mar 25. Med Oncol. 2012. PMID: 22447503 Clinical Trial.
-
Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention.Med Oncol. 2022 Jan 20;39(3):30. doi: 10.1007/s12032-021-01633-4. Med Oncol. 2022. PMID: 35059897 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous